A randomized, blinded, placebo-controlled clinical trial to evaluate longeveron mesenchymal stem cell (lmsc) therapy for treating the metabolic syndrome
Ended Project Grant Awarded Last action
- Award ID
- R42AG054322
- Recipient
-
Longeveron Inc. UEI PYXXAC2HV5T3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,051,486
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Miami, FL 33136, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $435,997 | |
| Amendment | $67,652 | |
| Amendment | -$38,244 | |
| Amendment | $38,244 | |
| Amendment | $22,521 | |
| Amendment | $397,837 | |
| Amendment | $0 | |
| Original award | $127,479 |
Quick answers
Who received award R42AG054322?
R42AG054322 was awarded to Longeveron Inc. by National Institute on Aging (National Institutes of Health) on September 30, 2017.
How much is award R42AG054322 worth?
$1,051,486 has been obligated on R42AG054322.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award